Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study reveals why diabetic cats are often misdiagnosed
Cat
“It has been common practice to automatically suspect a cat with Diabetes Mellitus to be suffering from a form of diabetes akin to human type 2."

One in four cases caused by hypersomatotropism

One in four cases of Diabetes Mellitus in cats are caused by excess secretion of pituitary growth hormone, according to research by the RVC.

The findings, published in PLOS ONE, reveal that this is much more common than previously thought, and cats with this condition can be easily misdiagnosed as having primary (type 2) diabetes.

Researchers collected data between 2003 and 2011 on over 1200 diabetic cats treated at veterinary practices across the UK.

They found that the presence of diabetes in one in four cats can be explained by hypersomatotropism - a state caused by a pituitary benign tumour which can be effectively treated by one operation in specialist centres.

However, just 24 per cent of clinicians who submitted samples suspected this was the case, as most hypersomatotropism cats did not display typical signs. Instead, they displayed symptoms indistinguishable from cats with primary (type 2) diabetes.  

The RVC say this suggests that hypersomatotropism screening should be considered when treating diabetic cats.   Lead researcher Dr Stijn Niessen, explains: 

“It has been common practice to automatically suspect a cat with Diabetes Mellitus to be suffering from a form of diabetes akin to human type 2.

"The current study suggests that this is an oversimplification. Approximately one in four of assessed diabetic cats were actually found to be suffering from hypersomatotropism-induced Diabetes Mellitus, which requires specific treatment and manifests itself very differently as it develops."

“Interestingly, only a small proportion of clinicians reported they strongly suspected acromegaly to be present on the basis of the clinical picture. These data therefore highlight the need for veterinarians working with the spontaneously diabetic cat to consider routinely screening for the presence of hypersomatotropism-induced Diabetes Mellitus, given the significant clinical consequences of its presence.

“Should the hypersomatotropism be diagnosed and treated with one operation, most cats will enter a state of diabetic remission. If it remains undiagnosed, diabetic cats tend to be difficult to regulate glycaemically which often results in euthanasia, or in the long-term, they will suffer from other growth hormone-induced negative conditions such as heart disease, as well as central nervous system problems.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.